Skip to main content
. 2020 May 4;15(5):e0232612. doi: 10.1371/journal.pone.0232612

Fig 2. Response of Ba/F3-gp130 cells with human or murine IL-6R to tocilizumab.

Fig 2

(A) Viability assay of Ba/F3-gp130-hIL-6R cells. Equal amounts of cells were stimulated with hIL-6 and incubated with different concentrations of tocilizumab as indicated for 48 h. Cell viability was measured and is shown in relative light units (RLU). One experiment out of three with similar outcome is shown. Data are shown as mean ± SD (n = 3). (B) The experiment was performed as described under (A) but with Ba/F3-gp130-mIL-6R cells and mIL-6. Data are shown as mean ± SD (n = 3). (C) Ba/F3-gp130-hIL-6R cells were pretreated with tocilizumab as indicated for 30 min and then stimulated with 10 ng/ml hIL-6 for 15 min. Phosphorylation of STAT3 was determined by western blot. Quantification of three independent experiments and one representative western blot is shown. (D) The experiment was performed as described under (C) but with Ba/F3-gp130-mIL-6R cells and mIL-6. Statistical significance was analyzed with one-way ANOVA followed by Dunnett's multiple comparisons test (***: p < 0.001; ns: not significant).